全球血液相關的聯盟 - 交易趨勢,企業,財務條件:2010年~2020年
市場調查報告書
商品編碼
939913

全球血液相關的聯盟 - 交易趨勢,企業,財務條件:2010年~2020年

Hematology Collaboration and Licensing Deals 2016-2023

出版日期: | 出版商: Current Partnering | 英文 100+ Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告提供全球血液相關市場上企業聯盟契約的締結趨勢與條件調查分析,最近的聯盟/契約情形與特徵,平均交易條件,代表性交易概要,大醫藥品企業趨勢,最近的聯盟交易清單等相關的系統性資訊。

目錄

摘要整理

第1章 簡介

第2章 血液相關的契約動向

  • 簡介
  • 過去數年的聯盟趨勢
  • 血液相關的聯盟:各交易類型
  • 血液相關的聯盟:各產業部門
  • 血液相關的聯盟:各開發階段
  • 血液相關的聯盟:各技術類型
  • 血液相關的聯盟:各治療適應症

第3章 血液相關的聯盟契約的財務條件

  • 簡介
  • 披露的財務條件
  • 契約總額
  • 預付款金
  • 里程碑付款金
  • 權利金比率

第4章 血液相關的交易與契約者

  • 簡介
  • 最活躍的經營者
  • 最活躍的經營者的清單
  • 主要契約:各契約金額

第5章 血液相關的契約文件名錄

  • 簡介
  • 文件披露的聯盟契約

第6章 血液相關的契約:各治療標的

  • 簡介
  • 交易:各治療標的

附錄

簡介目錄
Product Code: CP2207

Hematology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the hematology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of hematology deals from 2016 to 2023.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of hematology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in hematology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the hematology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in hematology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of hematology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of hematology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in hematology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Hematology Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse hematology collaboration and licensing deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Report scope

  • Hematology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of hematology trends and structure of deals entered into by leading biopharma companies worldwide.

Hematology Collaboration and Licensing Deals includes:

  • Trends in hematology dealmaking in the biopharma industry
  • Overview of collaboration and licensing deal structure
  • Directory of hematology deal records covering pharmaceutical and biotechnology
  • The leading hematology deals by value
  • Most active hematology licensing dealmakers

In Hematology Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type
  • Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
  • Hematology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Hematology Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse hematology collaboration and licensing deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in hematology dealmaking

  • 2.1. Introduction
  • 2.2. Hematology partnering over the years
  • 2.3. Hematology partnering by deal type
  • 2.4. Hematology partnering by industry sector
  • 2.5. Hematology partnering by stage of development
  • 2.6. Hematology partnering by technology type
  • 2.7. Hematology partnering by therapeutic indication

Chapter 3 - Financial deal terms for hematology partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for hematology partnering
  • 3.3. Hematology partnering headline values
  • 3.4. Hematology deal upfront payments
  • 3.5. Hematology deal milestone payments
  • 3.6. Hematology royalty rates

Chapter 4 - Leading hematology deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in hematology partnering
  • 4.3. List of most active dealmakers in hematology
  • 4.4. Top hematology deals by value

Chapter 5 - Hematology contract document directory

  • 5.1. Introduction
  • 5.2. Hematology partnering deals where contract document available

Chapter 6 - Hematology dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by hematology therapeutic target
  • Deal directory
  • Deal directory - Hematology deals by company A-Z 2016 to 2023
  • Deal directory - Hematology deals by technology type 2016 to 2023
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Hematology partnering since 2016
  • Figure 2: Hematology partnering by deal type since 2016
  • Figure 3: Hematology partnering by industry sector since 2016
  • Figure 4: Hematology partnering by stage of development since 2016
  • Figure 5: Hematology partnering by technology type since 2016
  • Figure 6: Hematology partnering by indication since 2016
  • Figure 7: Hematology deals with a headline value
  • Figure 8: Hematology deals with upfront payment values
  • Figure 9: Hematology deals with milestone payment
  • Figure 10: Hematology deals with royalty rates
  • Figure 11: Active hematology dealmaking activity since 2016
  • Figure 12: Top hematology deals by value since 2016